Page last updated: 2024-09-05

sorafenib and atrasentan

sorafenib has been researched along with atrasentan in 2 studies

Compound Research Comparison

Studies (sorafenib)	Trials (sorafenib)	Recent Studies (post-2010) (sorafenib)	Studies (atrasentan)	Trials (atrasentan)	Recent Studies (post-2010) (atrasentan)
6,520	730	5,251	358	41	108

Protein Interaction Comparison

Protein	Taxonomy	atrasentan (IC50)
Endothelin receptor type B	Homo sapiens (human)	0.2221
Endothelin-1 receptor	Homo sapiens (human)	0.0001
Endothelin-1 receptor	Rattus norvegicus (Norway rat)	0.0002
Endothelin receptor type B	Sus scrofa (pig)	0.315

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Tan, W	1
Espinosa, E; González, R; Merino, M; Pinto, A	1

Reviews

2 review(s) available for sorafenib and atrasentan

Article	Year
[Promising new treatment options for metastatic androgen-independent prostate cancer]. Actas urologicas espanolas, 2007, Volume: 31, Issue:6 Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Benzamides; Benzenesulfonates; Bevacizumab; Calcitriol; Cancer Vaccines; Docetaxel; Drug Screening Assays, Antitumor; Epothilones; Forecasting; Humans; Imatinib Mesylate; Male; Niacinamide; Phenylurea Compounds; Piperazines; Prostatic Neoplasms; Pyridines; Pyrimidines; Pyrrolidines; Randomized Controlled Trials as Topic; Salvage Therapy; Sorafenib; Taxoids; Thionucleotides	2007
Antiangiogenic agents and endothelin antagonists in advanced castration resistant prostate cancer. European journal of cancer (Oxford, England : 1990), 2011, Volume: 47, Issue:12 Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Atrasentan; Benzenesulfonates; Castration; Drug Resistance, Neoplasm; Endothelin Receptor Antagonists; Endothelins; Humans; Indoles; Lenalidomide; Male; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Pyrrolidines; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A	2011

Article

Year

[Promising new treatment options for metastatic androgen-independent prostate cancer].

Actas urologicas espanolas, 2007, Volume: 31, Issue:6

Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Benzamides; Benzenesulfonates; Bevacizumab; Calcitriol; Cancer Vaccines; Docetaxel; Drug Screening Assays, Antitumor; Epothilones; Forecasting; Humans; Imatinib Mesylate; Male; Niacinamide; Phenylurea Compounds; Piperazines; Prostatic Neoplasms; Pyridines; Pyrimidines; Pyrrolidines; Randomized Controlled Trials as Topic; Salvage Therapy; Sorafenib; Taxoids; Thionucleotides

2007

Antiangiogenic agents and endothelin antagonists in advanced castration resistant prostate cancer.

European journal of cancer (Oxford, England : 1990), 2011, Volume: 47, Issue:12

Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Atrasentan; Benzenesulfonates; Castration; Drug Resistance, Neoplasm; Endothelin Receptor Antagonists; Endothelins; Humans; Indoles; Lenalidomide; Male; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Pyrrolidines; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A

2011